Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiao'er Xiangru Granules in Pediatric Acute Upper Respiratory Tract Infection (TCM Wind-Heat with Dampness) – Phase II RCT
CTR20233165Phase 2Active
- Sponsor
- Yili Pharmaceutical
- Start
- Oct 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Xiao'er Xiangru Keli in upper respiratory infection (URI), nasopharyngitis, sponsored by Yili Pharmaceutical. Started Oct 2023; status: active.
02
Drugs
Xiao'er Xiangru Keli
03
Conditions
upper respiratory infection (URI)nasopharyngitis
Beyond the preview
Go deeper on CTR20233165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233165.